AbbVie Inc. (ABBV)
NYSE: ABBV
· Real-Time Price · USD
198.44
5.10 (2.64%)
At close: May 02, 2025, 3:59 PM
199.03
0.30%
After-hours: May 02, 2025, 05:52 PM EDT
2.64% (1D)
| Bid | 198.45 |
| Market Cap | 351.04B |
| Revenue (ttm) | 57.37B |
| Net Income (ttm) | 4.2B |
| EPS (ttm) | 2.34 |
| PE Ratio (ttm) | 84.8 |
| Forward PE | 13.93 |
| Analyst | Buy |
| Ask | 199 |
| Volume | 5,017,885 |
| Avg. Volume (20D) | 8,024,959.6 |
| Open | 195.17 |
| Previous Close | 193.34 |
| Day's Range | 194.63 - 198.96 |
| 52-Week Range | 153.58 - 218.66 |
| Beta | 0.54 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jan 2, 2013
Employees 55,000
Stock Exchange NYSE
Ticker Symbol ABBV
Website https://www.abbvie.com
Analyst Forecast
According to 21 analyst ratings, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $212, which is an increase of 6.83% from the latest price.
Stock ForecastsEarnings Surprise
AbbVie has released their quartely earnings
on Apr 25, 2025:
5 days ago
+3.38%
AbbVie shares are trading higher after multiple an...
Unlock content with
Pro Subscription
1 week ago
+3.15%
AbbVie shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.
